Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis
- 1 April 2017
- journal article
- Published by Elsevier in The American Journal of Medicine
- Vol. 130 (4) , 457-461
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trialThe Lancet, 2016
- Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial FibrillationThe American Journal of Medicine, 2016
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSEuropean Heart Journal, 2016
- Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapyEP Europace, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Thromboembolic Complications After Cardioversion of Acute Atrial FibrillationJACC, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementJournal of Clinical Epidemiology, 2009
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009